EMAIL THIS PAGE TO A FRIEND

European journal of endocrinology

Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review.


PMID 22577107

Abstract

This review addresses the practical usage of intravenous etomidate as a medical therapy in Cushing's syndrome. We reviewed the relevant literature, using search terms 'etomidate', 'Cushing's syndrome', 'adrenocortical hyperfunction', 'drug therapy' and 'hypercortisolaemia' in a series of public databases. There is a paucity of large randomised controlled trials, and data on its use rely only on small series, case study reports and international consensus guideline recommendations. Based on these, etomidate is an effective parenteral medication for the management of endogenous hypercortisolaemia, particularly in cases with significant biochemical disturbance, sepsis and other serious complications such as severe psychosis, as well as in preoperative instability. We suggest treatment protocols for the safe and effective use of etomidate in Cushing's syndrome.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

E6530
Etomidate, >98% (HPLC), powder
C14H16N2O2